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Abstract In this report, the first amphibian glucagon receptor
(GluR) cDNA was characterized from the liver of the frog Rana
tigrina rugulosa. Functional expression of the frog GluR in CHO
and COS-7 cells showed a high specificity of the receptor
towards human glucagon with an EC50 value of 0.8 þ 0.5 nM.
The binding of radioiodinated human glucagon to GluR was
displaced in a dose-dependent manner only with human glucagon
and its antagonist (des-His1-[Nle9-Ala11-Ala16]) with IC50 values
of 12.0 þ 3.0 and 7.8 þ 1.0 nM, respectively. The frog GluR did
not display any affinity towards fish and human GLP-1s, and
towards glucagon peptides derived from two species of teleost
fishes (goldfish, zebrafish). These fish glucagons contain
substitutions in several key residues that were previously shown
to be critical for the binding of human glucagon to its receptor.
By RT-PCR, mRNA transcripts of frog GluR were located in the
liver, brain, small intestine and colon. These results demonstrate
a conservation of the functional characteristics of the GluRs in
frog and mammalian species and provide a framework for a
better understanding of the molecular evolution of the GluR and
its physiological function in vertebrates.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Glucagon is a 29 amino acid peptide which belongs to a
large family of brain-gut peptides that includes glucagon-like
peptides (GLPs), gastric inhibitory polypeptide (GIP), pitui-
tary adenylate cyclase activating polypeptide (PACAP), vaso-
active intestinal polypeptide (VIP), secretin, growth-hormone
releasing factor (GRF) and peptide histidine methionine
(PHM). Glucagon is encoded in a precursor structure, prepro-
glucagon, which is di¡erentially processed to glucagon in K-
cells of the pancreas, and to GLP-1 and GLP-2 in the L-cells
of the small intestine [1,2]. Glucagon shows strong functional
and structural conservation across vertebrate species. The ma-
jor physiological functions of glucagon in mammals and ¢sh
are similar. Glucagon plays a central role in the physiology of
blood glucose regulation by inducing the processes of hepatic
glycogenolysis and gluconeogenesis [3,4]. However, some of
the actions of glucagon have diversi¢ed during evolution. Glu-
cagon is able to stimulate ureogenesis in mammals, but this
has not been demonstrated in ¢sh, including the ureogenic
toad¢sh, Opsanus beta [5]. In addition, the redundant e¡ects
of GLP-1 and glucagon in ¢sh [6,7]) make the functional and
evolutionary relationships between GLP-1 and glucagon in
vertebrates a fascinating story to investigate. Structurally,
the primary amino acid sequence of glucagon is conserved
across most vertebrates (Fig. 1) [7]. In addition to mammalian
glucagons [8], peptides or cDNAs corresponding to bird [9],
several species of frogs [10^13], bony ¢shes [14], cartilaginous
¢shes [15] and jawless ¢shes [16] have also been characterized.
The conservation of glucagon structure indicates that there
has been a strong evolutionary pressure to conserve the whole
glucagon molecule in vertebrates, and this ¢nding is consistent
with its central position in the regulation of metabolism.
The actions of glucagon are mediated via its speci¢c inter-
action with cell-surface receptors, hence, characterization of
the glucagon receptor (GluR) is a major step towards the
understanding of glucose metabolism. The glucagon receptor
belongs to a subfamily of the glucagon-secretin receptors in-
cluding glucagon, GLP-1 and GIP receptors. Like other fam-
ily members, GluR is a glycoprotein with a large hydrophilic
extracellular domain followed by seven highly conserved hy-
drophobic transmembrane helices. Recently, GluRs from rat
[17], human [18] and mouse [19] have been cloned and char-
acterized. Due to the central position of amphibians in verte-
brate evolution, the characterization of the frog GluR is able
to ¢ll a signi¢cant gap of our knowledge with respect to the
understanding of the evolutionary aspects of glucagon and
GLP-1 as well as their receptors in vertebrates.
2. Materials and methods
2.1. Cloning of the full-length frog Rana tigrina rugulosa glucagon
receptor cDNA
A partial cDNA clone corresponding to the transmembrane do-
mains (TMD) 2^6 of the putative frog GluR was obtained by a
two-step polymerase chain reaction (PCR) approach essentially fol-
lowing a protocol described earlier [20]. The partial cDNA clone was
used as a probe to screen a frog liver cDNA library (0.5 million
primary clones). The library was constructed using the Stratagene
ZAP-Express cDNA library system. 5 Wg of poly(A) RNA was
used and the number of primary clones obtained was 2.5 million. A
full-length cDNA clone (2.2 kb) encoding the frog GluR was isolated
and then excised to the phagemid, pBK-CMV-frogGR1. The clone
was sequenced from both strands using a T7 DNA sequencing kit
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(Pharmacia) by synthetic primers and by subcloning of restriction
fragments. DNA sequence was analyzed by DNasis v2.0 (Hitachi,
San Bruno, CA).
2.2. Functional expression of the frog glucagon receptor
2.2.1. Stimulation of intracellular cAMP in CHO cells expressing the
frog glucagon receptor. The bacterial lac promoter was released from
the construct pBK-CMV-frogGR1 by releasing a EcoRI/NheI restric-
tion fragment to produce the eukaryotic expression plasmid pBK-
CMV-frogGR. A permanent cell line, CHO-frogGR, expressing the
putative frog GluR was obtained by transfecting 10 Wg of pBK-CMV-
frogGR into 1 million CHO cells using the Lipofectamine reagent
(Gibco-BRL), and followed by G418 selection at 500 Wg/ml (Gibco-
BRL) for 2 weeks. Functional expression and cAMP assays were
performed as described earlier [20]. The cAMP level was measured
by radioimmunoassay using a cAMP assay kit (Amersham, Arlington
Heights, IL). All peptides used in this study were purchased from
Bachem Fine Chemicals, Inc. (Torrance, CA). Gold¢sh glucagon
was synthesized by Peninsula Laboratories, Inc. (Belmont, CA) and
was found to be able to stimulate cAMP production and bind specif-
ically to the gold¢sh GluR (unpublished results).
2.2.2. Competitive binding experiments with the frog glucagon
receptor. For the competitive binding experiments, the frog GluR
was expressed transiently into COS-7 cells using the standard protocol
[21]. In brief, COS-7 cells were grown to con£uence into 100 mm
plates, and transfected with 8 Wg pBK-CMV-frogGR using the
DEAE-dextran/chloroquine method. After 24 h, cells were transferred
into 24 well plates and cultured for an additional 24 h prior to the
binding assay. In the competitive binding experiments, 125I-human
glucagon (2200 Ci/mmol, receptor grade, NEN Life Science Products,
Boston, MA) was incubated with the COS-7 cells expressing the frog
GluR in the presence of increasing concentrations (pM^WM) of di¡er-
ent peptides for 16^18 h at 4‡C. The non-speci¢c binding was deter-
mined in the presence of 1 WM human glucagon and/or 1 WM gluca-
gon antagonist des-His1-[Nle9-Ala11-Ala16] [22]. Peptides were diluted
from a stock solution (10 WM) in the binding bu¡er prepared in
Hanks’ balanced salt solution containing 20 mM HEPES, pH 7.4,
0.5% BSA and 0.1 mM phenylmethylsulfonyl £uoride. Each peptide
concentration was added in triplicate wells. Following the incubation,
the cells were washed twice with ice-cold PBS, lysed with 1 M NaOH,
and radioactivity measured in a gamma counter. Total speci¢c bind-
ing was on average 45% of the total radioactivity added (1U105 cpm).
The glucagon antagonist des-His1-[Nle9-Ala11-Ala16] [22] was a gift
from Dr. Cecille Unson, while zebra¢sh glucagon was synthesized
by the Protein/DNA Technology Center of the Rockefeller University.
125I-zebra¢sh glucagon was found to bind speci¢cally to the gold¢sh
GluR transfected into COS-7 cells (Mojsov et al., unpublished re-
sults).
2.2.3. cAMP assays with the frog glucagon receptor expressed
transiently in the COS-7 cells. The ability of glucagon and its antag-
onist to stimulate intracellular cAMP was assayed in parallel with the
competitive binding experiments. The conditions of the incubations
were the same as the ones described for the CHO cells expressing the
frog GluR, with the exception that the cells were seeded into 24 well
plates, instead of 6 well plates. The levels of cAMP were determined
by the Enzyme Immunoassay Kit (Cayman Chemicals, Ann Arbor,
MI). To assess whether the glucagon antagonist is able to inhibit the
ability of glucagon to stimulate intracellular cAMP formation, the
antagonist was added to each well at 100 nM concentration prior to
the addition of increasing concentrations of glucagon (pM^WM). For-
skolin (100 nM) was used as a positive control in triplicate wells in
each plate.
2.3. Tissue distribution of the frog glucagon receptor mRNA
Tissue distribution of the frog GluR transcripts was studied by RT-
PCR. 3 Wg poly(A) RNA from individual tissues was used for the
preparation of ¢rst stand cDNA [20]. The sequences of PCR primers
are: GLU-5 TCCGTGCTTGTGAATGACACCATGC and GLU-3
GTCTGTGTACCTCATCTGATGAGC. PCR conditions were 1 min
at 94‡C, 1 min at 55‡C and 1 min at 72‡C for 30 cycles. The identity
of the PCR product was con¢rmed by Southern blotting using the
partial frog GluR cDNA fragment (443 bp) as a probe.
Fig. 1. Comparison of amino acid sequences of glucagon in vertebrate. Shaded areas represent identical amino acid residues. The chicken se-
quence is from [9], the Xenopus laevis from [11], bullfrog from [10], Bufo marinus from [14], and Rana sylvatica from [13]; the sequences from
di¡erent species of teleost ¢shes are adapted from [7] with the exception of glucagons from gold¢sh [14] and zebra¢sh [28].
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3. Results
3.1. Isolation of the frog glucagon receptor cDNA
The approach used to obtain partial GluR clones was based
on the ampli¢cation of partial VIP1 receptor cDNAs using
degenerate oligonucleotide primers [20]. The partial receptor
cDNA clone was subsequently used as a probe to screen a
frog liver cDNA library. A clone 2224 bp in length was ob-
tained and DNA sequence analysis of the putative GluR
cDNA clone revealed a single open reading frame of 1476
bp (from nucleotide 266 to 1741) encoding a protein of 492
amino acids (Fig. 2) with a predicted molecular weight of 56
kDa. The sequence homologies between the frog and human
or rat GluRs were 57% and 62%, respectively, at the cDNA
level, and 51% and 60% at the amino acid level. A Kyte-
Doolittle hydrophobicity analysis of the receptor indicated
that the protein is a G protein-coupled receptor with seven
segments of hydrophobic amino acids presumably forming the
transmembrane spanning regions and a hydrophobic signal
peptide at the N-terminus (data not shown).
3.2. Functional expression of the frog glucagon receptor
3.2.1. Stimulation of intracellular cAMP levels. To demon-
strate that the recombinant frog GluR expressed in mamma-
lian CHO cells could transduce a cellular signal, cAMP re-
sponses in the presence of various peptides were measured
(Fig. 3A). We used the human glucagon for the functional
characterization of the frog GluR because there is only one
conservative di¡erence (Ser-29 replacing Thr-29) at the C-ter-
mini of human and Rana tigrina rugulosa glucagons (Fig. 1).
More importantly, this residue was shown not to be involved
in the binding of human glucagon to its receptor [22,26,27].
Fig. 2. Amino acid sequence alignment of frog (top), rat, mouse and human GluRs by GeneWorks (IntelliGenetics). The arrows represent the
seven putative TMDs. Identical and conservative sequences are boxed. Conserved N-linked glycosylation sites and Cys residues among these
GluRs are labeled # and *, respectively.
Fig. 3. Stimulation of cAMP production in CHO-frog GluR cells. A: The cells were incubated with 100 nM of human (h), Xenopus (xen) and
gold¢sh (gf) glucagon and several structurally related peptides including hGLP-1, gfGLP-1, hGIP, hVIP, human secretin (hSEC), hPACAP-38,
exendin-4 and exendin (9^39). cAMP levels are expressed as fold stimulation compared to that of the control (no peptide). B: cAMP produc-
tion in CHO-frog GluR cells stimulated with various concentrations of hglucagon (F), hGLP-1 (8), gfglucagon (R), gfGLP-1 (S) and exen-
din-4 (b). Data presented here were from six independent peptide stimulations and the values are the means þ S.D. and the average values of
basal cAMP were 5.9 pmol/well.
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At a concentration of 100 nM, only human glucagon (Fig. 1),
but not gold¢sh glucagon was able to stimulate intracellular
cAMP production in the receptor-transfected cells. Other
structurally related peptides, such as human GLP-1, gold¢sh
GLP-1, human GIP, human secretin, human VIP, human PA-
CAP, exendin-4 and exendin (9^39), were also unable to stim-
ulate cAMP production. The cAMP stimulatory e¡ect of hu-
man glucagon was found to be dose-dependent with an EC50
value of 0.8 þ 0.5 nM (Fig. 3B). However, even at a concen-
tration of 1 WM, human and gold¢sh GLP-1s, gold¢sh gluca-
gon and exendin-4 were unable to activate the receptor (Fig.
3B).
3.2.2. Competitive binding experiments. For the competi-
tive binding experiments, 125I-human glucagon was able to
bind to the recombinant frog GluR transiently expressed in
mammalian COS-7 cells (45% speci¢c binding). The speci¢c
binding was displaced in a dose-dependent manner with hu-
man glucagon with an IC50 value of 12 þ 3 nM. The structur-
ally related GLP-1s (human and gold¢sh), as well as zebra¢sh
glucagon, were unable to displace the speci¢c binding of the
125I-human glucagon, while gold¢sh glucagon showed some
displacement only at a high concentration of 270 nM (Fig.
4A). One of the antagonists of the human GluR, des-His1-
[Nle9-Ala11-Ala16] [22], was used in the competitive binding
experiments to further characterize the binding properties of
the recombinant frog GluR. The antagonist was able to dis-
place the speci¢c binding of 125I-human glucagon in the same
concentration range as human glucagon with a similar IC50
value of 7.8 þ 1.0 nM (Fig. 4A). Based on these results, we
conclude that the frog GluR exhibits similar ligand binding
speci¢cities as the human GluR.
3.2.3. Functional e¡ects of the glucagon antagonist on the
frog glucagon receptor. To extend the comparisons of the
structural and functional properties of the frog and mamma-
lian GluRs, we tested the human glucagon antagonist des-
His1-[Nle9-Ala11-Ala16] and we found that it was unable to
stimulate intracellular cAMP levels in the concentration range
from 10 pM to 1 WM (Fig. 4B). In contrast, incubation of the
COS-7 cells that transiently expressed the frog GluR with
human glucagon led to a dose-dependent stimulation of intra-
cellular cAMP levels with EC50 = 0.8 nM, in agreement with
the results obtained from the initial functional experiments in
the CHO cells. More interestingly, incubation of the cells with
human glucagon in the presence of 100 nM antagonist shifted
the EC50 values from 0.8 nM to 2.7 nM (Fig. 4B) and inhib-
ited the stimulated cAMP levels by 43% (4.7-fold vs. 8.2-fold
in the absence of the antagonist) at a concentration of 1039
M. Together with the results obtained from the competitive
binding experiments, we established that the frog and human
GluRs share similar structural and functional properties.
3.3. Tissue distribution of frog glucagon receptor mRNA
To examine the tissue distribution of frog GluR, RT-PCR
was performed using ¢rst strand cDNAs prepared from var-
ious frog tissues, including skeletal muscle, brain, liver, small
intestine and colon, as templates. PCR products (443 bp) were
detected in all the tissues tested except in the muscle. The
authenticity of the PCR products was con¢rmed by Southern
blotting using the partial cDNA fragment as a probe (Fig. 5).
Fig. 4. Functional experiments with the frog GluR expressed transi-
ently in COS-7 cells. A: Competitive binding experiments measuring
the displacement of 125I-human glucagon binding in the presence of
increasing concentrations of hglucagon (b), the glucagon antagonist
des-His1-[Nle9-Ala11-Ala16] (R), gfglucagon (a), zebra¢sh glucagon
(8), gfGLP-1 (E), hGLP-1 (F). The results for hglucagon are an
average of six independent measurements, and for the other peptides
are averages of three independent measurements. Total speci¢c bind-
ing was on average 45% of the total radioactivity added (100 000
cpm). B: Stimulation of cAMP production. The results are ex-
pressed as fold stimulation of cAMP levels in response to increased
concentrations of hglucagon (a), glucagon antagonist des-His1-
[Nle9-Ala11-Ala16] (R) and hglucagon in the presence of glucagon
antagonist (100 nM) (O). The cAMP stimulations were performed
at least two times each in triplicate with two di¡erent batches of
transfected COS-7 cells. The average values for basal cAMP levels
were 15 pmol/well.
Fig. 5. Tissue distribution of frog GluR mRNA revealed by RT-
PCR. PCR products obtained from muscle, brain, liver, small intes-
tine and colon were subjected to Southern blot analysis using the
partial frog GluR cDNA as a probe.
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4. Discussion
In the present study, the ¢rst non-mammalian full-length
GluR cDNA was isolated and characterized. The N-terminal
ectodomain for this family of receptors has been shown to be
largely responsible for ligand speci¢city. Mutational analysis
of the glycine residue at position 40 of the human GluR
demonstrated that Gly-40 is involved in the structural deter-
mination of the extracellular ectodomain and the sensitivity of
the receptor to glucagon [23]. However, Gly-40 is not present
in the frog, rat and mouse GluRs. Since all these receptors can
interact with human glucagon, these data suggest that this
glycine residue plays a partial role in ligand binding and re-
ceptor stabilization.
A number of other residues are also involved in ligand
binding and receptor activation, such as Ser-80, Gln-142
and especially Asp-64 [24,25]. Functional characterization of
rat GluR [25] indicated that replacement of Asp-64 with Glu,
Asn, Lys or Gly results in the abolition of ligand binding. All
three residues are conserved in these GluRs, suggesting that
they are crucial to the binding of human glucagon with the
frog GluR to mediate cAMP responses. Functional character-
ization of the human GluR [24] revealed that Ser-80 and Gln-
142 are necessary for glucagon binding speci¢city. Both resi-
dues are conserved in the frog GluR. This observation may
account for the fact that the frog GluR interacts speci¢cally
with only human glucagon, but not with other related pepti-
des such as GLP-1 and GIP.
Several non-continuous domains that are required for high
a⁄nity binding with glucagon, including the membrane-prox-
imal half of the amino-terminal extension, the ¢rst exoloop,
the third, fourth, and sixth transmembrane domains [24], are
conserved among frog and mammalian GluRs. The conserva-
tion of these ligand recognition domains between the frog and
human GluRs may further explain the speci¢city of the frog
GluR towards the structure of human glucagon.
In addition, the results of our competitive binding experi-
ments demonstrated that the frog and human GluRs contain
similar, if not identical, binding a⁄nity towards the active site
of glucagon structure. These conclusions are based on the
following observations. First, the frog GluR binds the human
GluR antagonist des-His1-[Nle9-Ala11-Ala16] with the same
a⁄nity as the human GluR (Fig. 4A and [22]). Second, the
frog GluR did not bind to gold¢sh and zebra¢sh glucagons.
The lack of binding speci¢city of the frog GluR towards the
gold¢sh and zebra¢sh glucagons is consistent with the pro-
posed mechanism of the interaction of the human glucagon
with the human GluR [26,27]. According to this mechanism,
His-1, Asp-9 and Ser residues are essential amino acids needed
for the formation of the active center of the human glucagon/
glucagon-receptor system. Of the four Ser residues present in
the sequence of human glucagon, Ser-8 and to a lesser extent
Ser-16 are critical residues needed for the formation of the
active center of glucagon. Thus, the substitution of Ser-8
with an Asn residue decreased the binding a⁄nity of [Asn8]
glucagon to 8% as compared to the naturally occurring glu-
cagon [27]. Similarly, substitution of the Ser-16 with a Thr
residue led to an analog that possessed about 8% binding
a⁄nity [27]. Finally, substitution of Asp-15 with Glu resulted
in an analog that contained about 80% of the binding a⁄nity
[27]. Clearly, the triple substitutions of Ser8, Asp15 and Ser16
with Asn8, Glu15, and Thr16 found in the sequences of gold-
¢sh and zebra¢sh glucagons leads to a disruption of this ac-
tive center and hence there was a complete loss of binding
a⁄nity of the frog GluR towards these ¢sh glucagons.
As seen from Fig. 1, the same substitutions in amino resi-
dues at identical positions of the sequence are found in the
glucagons in all teleost ¢shes analyzed so far, suggesting that
the GluRs in species that existed before the appearance of the
frogs would have di¡erent ligand binding speci¢cities. Taken
together, these observations indicate that evolutionary pres-
sures manifested at the time of the emergence of the frog
species may have directed simultaneous changes in the sequen-
ces of glucagon and sequences of the ligand recognition do-
mains of GluRs. As a result, starting with the frog species,
more stringent structural constraints were developed in the
glucagon/glucagon-receptor system and were maintained sub-
sequently during the evolution in the mammalian species. Fur-
ther experiments and especially functional characterization of
¢sh GluRs are needed in order to understand the structural
evolution of vertebrate glucagons and their receptors.
The frog glucagon and GLP-1s may have unique functions
probably by interacting with multiple glucagon/GLP-1 recep-
tors that are expressed in a tissue-speci¢c manner. In the
present study, the tissue distribution of the GluR mRNA
was investigated as a preliminary step to understand the glu-
cagon/GLP-1 system in Rana tigrina rugulosa. Similar to other
species, GluR mRNA is present at high levels in the liver,
gastrointestinal tract and brain. The expression of GluR tran-
scripts in the liver is consistent with the major functions of
glucagon, which are the stimulation of hepatic glycogenolysis
and gluconeogenesis. In summary, our results demonstrate a
conservation of the functional characteristics of the GluRs in
frog and mammalian species and provide a framework for a
better understanding of the molecular evolution of the GluR
and its physiological function in vertebrates.
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